Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Long-Term Investments (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Long-Term Investments for 6 consecutive years, with $470.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Investments fell 28.39% to $470.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $470.5 million, a 28.39% decrease, with the full-year FY2025 number at $470.5 million, down 28.39% from a year prior.
  • Long-Term Investments was $470.5 million for Q4 2025 at Relay Therapeutics, down from $504.9 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $847.1 million in Q4 2022 to a low of $387.9 million in Q3 2021.
  • A 5-year average of $619.7 million and a median of $636.9 million in 2024 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: surged 194.23% in 2021, then dropped 28.42% in 2023.
  • Relay Therapeutics' Long-Term Investments stood at $678.0 million in 2021, then rose by 24.95% to $847.1 million in 2022, then decreased by 28.42% to $606.4 million in 2023, then increased by 8.36% to $657.0 million in 2024, then fell by 28.39% to $470.5 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Long-Term Investments are $470.5 million (Q4 2025), $504.9 million (Q3 2025), and $542.8 million (Q2 2025).